Surgery Websites
LiverSource »  Faculty »  Medical Oncology »  Emily Bergsland, M.D.
Emily Bergsland, M.D.

Emily Bergsland, M.D.

Professor of Clinical Medicine
Division of Hematology Oncology
Department of Medicine
Ernest Rosenbaum, MD Endowed Chair of Medical Oncology

Contact Information

1825 Fourth St., Fourth Floor
San Francisco, CA 94158
Phone: (415) 353-9888
Fax: (415) 353-9931


Open Popup
  • UniversUniversity of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
  • University of Minnesota, M.D., 1982
  • 1989-92, Intern, Dept. of Medicine, University of California San Francisco
  • 1990-92, Resident, Dept. of Medicine, University of California San Francisco
  • 1992-92, Chief Resident and Assistant Chief of the Medical Service, Dept. of Medicine, University of California San Francisco
  • 1993-92, Fellow, Medical Oncology, University of California San Francisco
  • 1994-1992, Research Fellow (P I: Douglas Hanahan, Ph.D.), Department of Biochemistry and Biophysics, University of California San Francisco
  • American Board of Internal Medicine
  • American Board of Internal Medicine: Medical Oncology - Subspecialty
  • Colon Cancer
  • Esophageal Cancer
  • Liver Cancer
  • Lynch Syndrome
  • Pancreatic Cancer
  • Rectal Cancer
  • Stomach Cancer
  • Angiogenesis Inhibitors
  • Colorectal Neoplasms
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Vascular Endothelial Growth Factor

Dr. Emily Bergsland is currently a Professor of Clinical Medicine and holds the Ernest Rosenbaum, MD Endowed Chair of Medical Oncology. She received her medical degree from the University of Minnesota and completed an internship, residency, and chief residency in internal medicine at UCSF. She subsequently completed a fellowship in Medical Oncology and was a Molecular Medicine fellow before joining the UCSF faculty in 1998.

Dr. Bergsland has led numerous clinical studies in patients with gastrointestinal malignancies. Her current efforts are focused on clinical and translational research related to neuroendocrine tumors. At a national level, Dr. Bergsland is a member of the Neuroendocrine Tumor Task force for the National Cancer Institute and a member of the NCCN NET guidelines panel. She is also the study chair for a national study of a novel treatment for patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute.

Bergsland And Nakakura

Most recent publications from a total of 84
  1. Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Netw. 2018 Jun; 16(6):693-702. View in PubMed
  2. Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH. Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clin Ther. 2018 Apr 30. View in PubMed
  3. Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti DB. Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl. Clin Ther. 2017 Nov; 39(11):2158-2168. View in PubMed
  4. Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018 Jan; 59(1):66-74. View in PubMed
  5. Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP. Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series. Fam Cancer. 2017 Oct; 16(4):537-543. View in PubMed
  6. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul; 46(6):707-714. View in PubMed
  7. Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017 Jul; 46(6):715-731. View in PubMed
  8. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist. 2017 Jul; 22(7):768-773. View in PubMed
  9. Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E. Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices. Med Oncol. 2017 May; 34(5):88. View in PubMed
  10. Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA. Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer. J Immunother Cancer. 2017; 5:22. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Emily Bergsland, M.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

Site Directory
    X